One study found that an IFN-γ-related mRNA profile in TILs was correlated with response to PD-1 inhibition [34], while a separate study found that high baseline levels of tumoural IFN-γ mRNA were associated with the higher response rate in durvalumab-treated NSCLC patients [35]. Here, IFNG is linked to non-small cell lung carcinoma.